However, the sheer number of pre-clinical and clinical trials being conducted with Pim inhibitors demonstrates the clinical significance of targeting the Pim pathway in lymphoproliferative disorders and solid tumors. Here, PIM1 is linked to lymphoproliferative syndrome.